Author: David Cooper

Downloads per author, site-wide

Preprints

Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report

• Downloaded 69,374 times
• Download rankings, all-time:
  • Site-wide: 78
  • In infectious diseases: 29
• Year to date:
  • Site-wide: 229
• Since beginning of last month:
  • Site-wide: 255

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

• Downloaded 66,567 times
• Download rankings, all-time:
  • Site-wide: 85
  • In infectious diseases: 34
• Year to date:
  • Site-wide: 98
• Since beginning of last month:
  • Site-wide: 228

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 57,003 times
• Download rankings, all-time:
  • Site-wide: 101
  • In microbiology: 8
• Year to date:
  • Site-wide: 11
• Since beginning of last month:
  • Site-wide: 495

Neutralization of spike 69/70 deletion, E484K, and N501Y SARS-CoV-2 by BNT162b2 vaccine-elicited sera

• Downloaded 40,147 times
• Download rankings, all-time:
  • Site-wide: 156
  • In microbiology: 13
• Year to date:
  • Site-wide: 24
• Since beginning of last month:
  • Site-wide: 75

Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine

• Downloaded 23,247 times
• Download rankings, all-time:
  • Site-wide: 310
  • In infectious diseases: 114
• Year to date:
  • Site-wide: 569
• Since beginning of last month:
  • Site-wide: 1,089

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

• Downloaded 14,161 times
• Download rankings, all-time:
  • Site-wide: 546
  • In infectious diseases: 188
• Year to date:
  • Site-wide: 135
• Since beginning of last month:
  • Site-wide: 266